I-123 Biomarker Committee: Difference between revisions

Revision as of 15:26, 11 July 2018

Co-chairs: John Dickson, PhD; John Seibyl, MD

Secretary: Julie Lisiecki

Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases

Revision as of 15:24, 11 July 2018 view source Jlisiecki (talk \| contribs) Bureaucrats, Administrators 7,000 edits Created page with "{{TOCright}} :Co-chairs: John Dickson, PhD; John Seibyl, MD :Secretary: Julie Lisiecki * [http://tinyurl.com/QIBA-SPECT-Roster Roster] ==Recent Meetings/Call Summaries== *[..."		Revision as of 15:26, 11 July 2018 view source Jlisiecki (talk \| contribs) Bureaucrats, Administrators 7,000 edits mNo edit summary Newer edit →
Line 5:		Line 5:


			Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases

	==Recent Meetings/Call Summaries==		==Recent Meetings/Call Summaries==